JPWO2022192790A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022192790A5
JPWO2022192790A5 JP2023555534A JP2023555534A JPWO2022192790A5 JP WO2022192790 A5 JPWO2022192790 A5 JP WO2022192790A5 JP 2023555534 A JP2023555534 A JP 2023555534A JP 2023555534 A JP2023555534 A JP 2023555534A JP WO2022192790 A5 JPWO2022192790 A5 JP WO2022192790A5
Authority
JP
Japan
Prior art keywords
methoxy
nonan
diazabicyclo
fluoro
fluoroquinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510207A5 (https=
JP2024510207A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/020230 external-priority patent/WO2022192790A1/en
Publication of JP2024510207A publication Critical patent/JP2024510207A/ja
Publication of JPWO2022192790A5 publication Critical patent/JPWO2022192790A5/ja
Publication of JP2024510207A5 publication Critical patent/JP2024510207A5/ja
Pending legal-status Critical Current

Links

JP2023555534A 2021-03-12 2022-03-14 Kras阻害剤 Pending JP2024510207A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163160436P 2021-03-12 2021-03-12
US63/160,436 2021-03-12
US202163288965P 2021-12-13 2021-12-13
US63/288,965 2021-12-13
PCT/US2022/020230 WO2022192790A1 (en) 2021-03-12 2022-03-14 Kras inhibitors

Publications (3)

Publication Number Publication Date
JP2024510207A JP2024510207A (ja) 2024-03-06
JPWO2022192790A5 true JPWO2022192790A5 (https=) 2025-03-25
JP2024510207A5 JP2024510207A5 (https=) 2025-03-25

Family

ID=81074021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555534A Pending JP2024510207A (ja) 2021-03-12 2022-03-14 Kras阻害剤

Country Status (11)

Country Link
US (1) US20240217982A1 (https=)
EP (1) EP4305037B1 (https=)
JP (1) JP2024510207A (https=)
KR (1) KR20230169968A (https=)
AU (1) AU2022232460A1 (https=)
BR (1) BR112023017661A2 (https=)
CA (1) CA3210383A1 (https=)
ES (1) ES3014892T3 (https=)
IL (1) IL305572A (https=)
MX (1) MX2023010429A (https=)
WO (1) WO2022192790A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
JP2024517695A (ja) * 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法
WO2023114733A1 (en) * 2021-12-13 2023-06-22 Quanta Therapeutics, Inc. Kras modulators and uses thereof
AU2023218370B2 (en) 2022-02-09 2024-11-28 Quanta Therapeutics, Inc. Kras modulators and uses thereof
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
CN118344386A (zh) * 2023-01-13 2024-07-16 苏州泽璟生物制药股份有限公司 取代桥环类抑制剂及其制备方法和应用
CN119317628A (zh) * 2022-03-22 2025-01-14 苏州泽璟生物制药股份有限公司 取代桥环类抑制剂及其制备方法和应用
JP7676677B2 (ja) * 2022-03-25 2025-05-14 イーライ リリー アンド カンパニー Kras阻害剤
IL317601A (en) 2022-05-25 2025-02-01 Quanta Therapeutics Inc Pyrimidine-based modulators and their uses
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
TW202416976A (zh) * 2022-09-16 2024-05-01 大陸商南京明德新藥研發有限公司 含六氫螺環[環丙烷—1,2'—吡咯𠯤]的化合物
WO2024061365A1 (zh) * 2022-09-22 2024-03-28 成都奥睿药业有限公司 嘧啶并环类化合物及其制备方法与用途
JP2025536369A (ja) 2022-10-21 2025-11-05 リーディングタック ファーマシューティカル(シャオシン)カンパニー,リミテッド Kras g12d分解剤及びその製造方法並びに応用
EP4631942A1 (en) 2022-10-21 2025-10-15 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. Pan-kras degrading agent, and preparation method therefor and use thereof
CN121419983A (zh) 2023-01-26 2026-01-27 阿尔维纳斯运营股份有限公司 基于小脑蛋白的kras降解protac及其相关用途
WO2024192424A1 (en) 2023-03-15 2024-09-19 Quanta Therapeutics, Inc. Kras modulators and uses thereof
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
AU2018271990A1 (en) * 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
US20220363681A1 (en) * 2019-08-16 2022-11-17 Genfleet Therapeutics (Shanghai) Inc. Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof
US20230081426A1 (en) * 2020-09-18 2023-03-16 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
WO2022173870A1 (en) * 2021-02-09 2022-08-18 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof

Similar Documents

Publication Publication Date Title
JPWO2022192790A5 (https=)
JPWO2022192794A5 (https=)
IL295799A (en) Trophomyosin receptor kinase (trk) degradation compounds and methods of use
JP2025016684A5 (https=)
US9199979B2 (en) Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
ES2616679T3 (es) Nuevos derivados de indolizina, procedimiento para su preparación y composiciones farmacéuticas que los contienen para el tratamiento del cáncer
JP2025535046A (ja) Kras g12c変異タンパク質の複素環阻害剤及びその使用
JP2007538092A5 (https=)
JP7320652B2 (ja) ピラゾールmagl阻害剤
FI4083038T3 (fi) Pyridatsinyylitiatsolikarboksiamidiyhdiste
RU2014119250A (ru) Производные 8-карбамоил-2-(2,3-дизамещенного пирид-6-ил)-1,2,3,4-тетрагидроизохинолина в качестве индуцирующих апоптоз средств для лечения рака и иммунных и аутоиммунных заболеваний
JP2017530185A5 (https=)
JP2016517878A5 (https=)
JP2011500702A5 (https=)
JPWO2021055744A5 (https=)
JP2005508923A5 (https=)
JPWO2020061101A5 (https=)
CN106573006A (zh) 作为药物的rip1激酶抑制剂杂环酰胺
JPWO2022223025A5 (https=)
RU2007116039A (ru) Сульфонилзамещенные бициклические соединеия в качестве модуляторов ppar
RU2011119478A (ru) Соединения и способы применения
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
JP2008528467A5 (https=)
JP2006524254A5 (https=)
JP2007519694A5 (https=)